Status:
UNKNOWN
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
Lead Sponsor:
University Hospital, Brest
Conditions:
Glioblastoma Multiforme
Anaplastic Astrocytoma
Eligibility:
All Genders
18+ years
Brief Summary
Glioblastoma is the most common malignant brain tumor in adults. The primary treatment consists of maximal tumor removal followed by radiotherapy (RT) with concomitant and adjuvant temozolomide. Tumor...
Eligibility Criteria
Inclusion
- 18 Years or older
- Histologically confirmed newly diagnosed glioblastoma or anaplastic astrocytoma
- Patients must have undergone surgery with macroscopic complete resection or incomplete resection with residual disease less than 5 cm on MRI
- An MRI or a scan 48h after surgery should be available
- WHO ≤ 2
- Indication for adjuvant radiotherapy
- Surgery must have been performed 45 days before the start of radiotherapy.
- Ability to understand and to give consent
Exclusion
- Age \< 18 Years.
- Prior radiation therapy to the brain
- Any usual formal indication against MRI (claustrophobia, metallic objects or implanted medical devices in body: pacemaker, clips, prostheses ...)
- Allergic reaction to FET
- Pregnant women or nursing mothers
- Refusal to use effective contraception at study entry and throughout the study if patient is of childbearing age.
Key Trial Info
Start Date :
October 31 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03370926
Start Date
October 31 2016
End Date
October 31 2019
Last Update
December 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609